Neuland Laboratories Ltd. Share Price

Neuland Laboratories: Strong Prior Trend, Deeper Correction

stock had a strong advance from roughly ₹12,000 in March to above ₹24,000 in early September, but the latest price action shows that the rally has shifted into a corrective phase. The moving averages now confirm that change in momentum. Price is below the 20-day moving average at ₹22,097 and below the 50-day moving average at ₹22,610. The 20-day average has turned lower and is moving away from the 50-day average, showing that the recent selling pressure is not limited to a single weak session. ₹22,097 is the first recovery level to watch. A move above it would indicate that price is attempting to regain short-term momentum. However, the more important resistance is ₹22,610, where the 50-day moving average sits. A sustained close above ₹22,610 would suggest that the correction is stabilising and could bring ₹23,000–₹23,500 back into focus. On the downside, ₹21,500 is the immediate support zone. A close below it could expose ₹21,000, followed by the August breakout area near ₹20,000. That zone is important because it was the base before the sharp August rally. Holding above ₹21,500 would keep the current move in the category of a controlled correction; losing it would raise the possibility of a deeper retracement. Neuland’s pharmaceutical API and CRAMS exposure provides a long-term business theme, but the chart currently calls for caution. The larger uptrend is not broken yet, though price needs to reclaim the 20-day and 50-day averages before the next upward leg can be considered confirmed.

See More

Swing Bullish Strategy – Eagle Momentum (Weekly)

Swing Bullish Strategy – Eagle Momentum (Weekly)

has been outperformed Nifty 500 over last 1 week. The Weekly Eagle Momentum strategy focuses on identifying stocks showing strong short-term relative strength compared to the broader market. It selects stocks that have outperformed the benchmark over the last 1 week, indicating strong buying interest and emerging momentum. Traders use this strategy to identify stocks that may continue their short-term upward momentum, making them suitable candidates for swing trades. Traders typically combine this with price structure, volume strength, and support levels to identify potential entries while maintaining disciplined risk management. Disclaimer: Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. The above analysis is for educational and learning purpose. SEBI Registered Research Analyst: Vineet Ashwinikumar Chawla: INH000008190, BSE Enlistment No: 5433

See More

Neuland Laboratories: Land-Banking company

CMP: ₹23,995 - a new high, near/above the previous 52-week high (₹23,899) Price Movement: The stock has more than doubled over the past year (from a 52-week low of ₹11,500), with strong 1-month momentum. It's now trading at fresh highs, and technicals have stayed bullish with RSI readings near overbought territory.

's board approved ₹126 crore to acquire 134 acres in Kakinada, Andhra Pradesh (plus ROFR on 66 more acres), funded entirely through internal accruals, no debt, no dilution. Positives: Debt-free capacity planning, strong multi-year price trend, sustained institutional confidence. Concerns: No disclosed plant timeline or capex plan yet, this is land-banking, not new output. Valuation is rich (PE 50-60x+), and the stock is at all-time highs, leaving little margin of safety. Why it stands out right now: Tomorrow, September 9, is confirmed as a genuinely rare event - six mainboard IPOs open on the same day, together raising roughly ₹4,400–4,500 crore. Multiple sources describe this as the biggest single-day IPO rush in 30 years.

See More

Neuland Laboratories: ₹126 Cr Land Acquisition

is in focus after its board approved a ₹126 crore capital expenditure for the purchase of approximately 134 acres of land at Kakinada, Andhra Pradesh. The company has also secured a right of first refusal to acquire an additional contiguous land parcel of approximately 66 acres at a later stage, which could take the potential aggregate land holding at the location to around 200 acres. Neuland Laboratories has indicated that the land is intended to support the company’s future expansion plans. The acquisition provides the company with additional land capacity for potential development and expansion of its operations in the future. Investors will be watching how the company plans to utilise the land, the timing of subsequent development and the capital expenditure associated with future projects. The announcement puts Neuland Laboratories in focus as the company moves ahead with its longer-term expansion plans.

See More

Neuland Laboratories in Focus After Expansion Plan

Neuland Laboratories is in focus after its board approved a ₹126 crore capital expenditure for acquiring approximately 134 acres of land at Auro Industrial City in Kakinada, Andhra Pradesh. The company plans to use the land for its future expansion requirements, providing a potential foundation for additional manufacturing and business capacity. The entire investment will be funded through internal accruals, meaning the company does not need to depend on fresh debt for the acquisition. Neuland has also secured a right of first refusal for another contiguous parcel of around 66 acres, which could eventually take its total land holding at the location to nearly 200 acres. The expansion plan indicates that the company is preparing for longer-term growth and capacity requirements. Investors are likely to monitor how the land is subsequently utilised and whether new manufacturing facilities or other expansion projects are announced. The use of internal accruals also keeps the balance sheet impact relatively manageable. The development could provide a positive long-term trigger for the stock, while execution and future capital deployment will remain important factors.

See More

Neuland Laboratories in Focus After ₹126 Cr Expansion Bet

Neuland Laboratories is in focus on September 8 after approving ₹126 crore capex for 134 acres in Kakinada. The stock has gained 50.46% YTD in CY2026. Neuland Laboratories Ltd. (NSE:

) could be in focus today, September 8, 2026, after the company announced a major expansion move in Andhra Pradesh. The company’s Board has approved ₹126 crore in capital expenditure to purchase approximately 134 acres of land in Kakinada. Neuland also has a right of first refusal to acquire another contiguous parcel of around 66 acres, potentially taking its total landholding at the location to nearly 200 acres. According to the company, the land acquisition is intended to support its future expansion plans. The announcement comes after a strong run in the stock. Neuland Laboratories shares closed at ₹22,870 on September 7, up 0.93% for the day. The stock’s 52-week high stands at ₹23,881. Neuland Laboratories has gained an impressive 50.46% year-to-date in CY2026, while rising 13.55% over the past month. However, the stock declined 2.35% during the last one week. With a market capitalisation of ₹29,368 crore and a P/E ratio of 59, investors may watch whether the expansion announcement acts as another catalyst for the stock in the coming sessions. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More